Dr. Mohamed Kharfan-Dabaja covered CAR T-cell therapy for B-cell lymphomas, showing 5-year survival of 42.6% in mantle cell cases and 64% in early remissions. Early use improved PFS. Prognostic factors included male sex, LDH, and bilirubin. Despite risks like secondary cancers, benefits extend even to octogenarians.